Overview
- Management raised fiscal 2026 guidance for net sales to $308 million to $313 million, increased targets for MedTech growth, adjusted EBITDA and adjusted EPS, and reaffirmed positive free cash flow.
- First-quarter revenue reached $75.71 million versus $72.73 million expected, with a loss of $0.10 per share topping the forecasted $0.12 loss.
- The MedTech segment, including AngioVac and AlphaVac, delivered its fourth consecutive quarter of more than 20% revenue growth.
- Gross margin improved by 90 basis points year over year in the quarter, supported by the higher-growth MedTech mix.
- Shares climbed to just above $12 after the report, and the company now projects a full-year loss of $0.23 to $0.33 per share.